10 Best Stocks Under $10 Offering More Than 50% Upside
Despite war-related risks to consumer spending and inflation, SCFR remains optimistic about the broader U.S. economy and the stock market.
Voyager Therapeutics Inc. (VYGR)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 3,500,000 | $13,510,000 | -13% | 0.24% |
| 2. | Millennium Management Israel Englander | 3,428,571 | $13,234,284 | +83% | 0.01% |
| 3. | Vestal Point Capital Ryan Wilder | 3,002,936 | $11,591,333 | +104% | 0.32% |
| 4. | Opaleye Management James A. Silverman | 1,150,000 | $4,439,000 | -4% | 0.58% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 615,660 | $2,376,448 | +884% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.88 | 4,395,588 | $39,032,821.44 | 8,575,316 | 2023-02-23 | Filing | |
| $5.66 | 376,000 | $2,126,543.20 | 4,753,907 | 2022-06-23 | Filing | |
| $5.28 | 101,400 | $535,503.54 | 4,377,907 | 2022-06-21 | Filing | |
| $11.96 | 4,179,728 | $49,999,996.20 | 4,179,728 | 2019-03-12 | Filing | |
| $19.39 | 3,000 | $58,170.00 | 76,588 | 2018-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.87 | 11,511 | $44,547.57 | 472,549 | 2026-04-02 | Filing | |
| $3.77 | 6,458 | $24,346.66 | 199,738 | 2026-02-24 | Filing | |
| $3.79 | 14,197 | $53,806.63 | 484,060 | 2026-02-24 | Filing | |
| $3.77 | 4,668 | $17,598.36 | 151,416 | 2026-02-24 | Filing | |
| $3.76 | 4,174 | $15,694.24 | 145,718 | 2026-02-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 172 | $602 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage
On November 12, HC Wainwright lowered the price target on Voyager Therapeutics, Inc. (NASDAQ:VYGR) to $25 from $30 and kept a Buy rating on the shares.
11 Best Micro-Cap Stocks to Invest in According to Analysts
Micro-cap companies, generally referring to publicly traded businesses with less than $300 million in market capitalization, are among the most volatile and high-risk investments in the stock market.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Voyager Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Voyager Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note that today's conference is being recorded.
Hedge Fund Resource Center